Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could donor cells stop MS progression? early trial launches

NCT ID NCT07477639

Recruiting now Disease control Sponsor: Tr1X, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a cell therapy called TRX319 in 39 adults with progressive multiple sclerosis (MS). The goal is to see if it is safe and to find the best dose. Participants receive TRX319 infusions, sometimes after a chemotherapy drug called bendamustine, and are followed for one year with blood tests, MRI scans, and spinal taps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TRX319 (a cell therapy made from donor cells) and bendamustine (a chemotherapy drug used to prepare the body)
What this could lead to
If it works, this could point toward a new treatment that slows or stops worsening disability in progressive multiple sclerosis.
What could go wrong
This is a very early, small trial (39 people) focused on safety. The therapy may not work, and side effects from the cell infusion or bendamustine could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (MS) SECONDARY PROGRESSIVE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • Washington University, St. Louis

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.